Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
The U.S. in vitro diagnostics market is estimated to grow at a compound annual growth rate of 4.9% during the forecast period 2018 to 2024. The market revenue (in USD million) is estimated from 2019 to 2024. In vitro diagnostics market can be segmented on the basis of type, techniques, applications and end users. By type the market is segmented in to instruments, reagents, data management software and services. By in vitro diagnostics techniques market is segmented in to immunoassay, clinical chemistry, microbiology, molecular diagnostics, hematology, coagulation & hemostasis and others. The major applications studied in the report of in vitro diagnostics technologies are, infectious diseases, cancer/oncology, endocrinology, cardiology, diabetes, nephrology and others. Major end users of the in vitro diagnostics technologies are, hospitals, clinical laboratories, academic & research institutes, physician offices, patient-self testing and others. The United States in vitro diagnostics market is dominated by key players Abbott Diagnostics, Alere, Beckman Coulter, Becton Dickinson, Biomerieux, Danaher Corporation, Hologic, Ortho-Clinical Diagnostics, QIAGEN, Roche Diagnostics, Siemens Healthcare Diagnostics, Sysmex Corporation and Thermo Fisher Scientific. The company profiles of the leading companies include, key financials, detailed product portfolio, last 4 years recent developments etc. The report also covers competitive deals such as, merger and acquisitions, new product launches, agreements, new business channels etc. of the United States in vitro diagnostics market of last 4 years. The factors driving the United States in vitro diagnostics market are, growing population of boomers and prevalence of the chronic and contagious diseases, growing preference of the point-of-care testing diagnostics devices and government initiatives to promote healthcare domain etc. Alongside the growth of the market inhibited due to the unfavorable reimbursement, Stringent regulatory framework etc.
Why to buy this report: